Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CVM vs CLYM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–2 Matrix Metrics)

CLYM Overall Winner 6-Pillar Tally: CVM 2 – 3 CLYM (1 Tie) Matrix Metrics: CVM 2 – 6 CLYM

As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas CLYM carries 45.7/100 (HOLD) at $9.64 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs CLYM
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.91
+14.76% 1D
Market Cap $22.5M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.45β · 139% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 61.8 · SMA20: $1.48 · SMA50: $1.67
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.64
-3.02% 1D
Market Cap $608.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.52β · 112% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 41.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 43
RSI-14: 43.4 · SMA20: $10.22 · SMA50: $11.34

6-Pillar Scorecard Institutional Category Breakdown (CVM 2 – 3 CLYM)

Columns: Metric · CVM · CLYM
1. Valuation Multiples CVM
Forward P/E 23.0x N/M
Trailing P/E 23.0x N/M
PEG Ratio 1.12x N/M
EV / Revenue N/M N/M
2. Growth & Scale CLYM
Revenue Growth (YoY) -62.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28,558 N/A
Market Cap $22.5M $608.5M
3. Profitability & Quality CLYM
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -252.5% -29.3%
4. Balance Sheet & Cash Flow CVM
Cash Generation (TTM) -$17M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $3.95 Book/Sh · -29.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CLYM
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (2) vs CLYM (6)
Institutional Metric CVM CLYM Criterion Row Edge
Market Capitalization
Scale
$22.5M $608.5M Larger Scale CLYM
Trailing P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Forward P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Revenue Growth (YoY)
Growth
-62.7% +0.0% Higher Growth CLYM
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-252.5% -29.3% Higher ROE CLYM
52-Week Range Position
Momentum
15% ($1–$8) 48% ($2–$18) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
0.45β · 139% Vol 1.52β · 112% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 45.7 / 100 (HOLD) Higher Composite CLYM
Trailing 12M Revenue (USD)
Operating Scale
$28,558 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) N/A ($3.95 Book/Sh · -29.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVM +16.37 pp
CVM: +15.45% · CLYM: -0.92%
3M Horizon CVM +60.57 pp
CVM: +16.16% · CLYM: -44.41%
6M Horizon CVM +19.91 pp
CVM: +19.81% · CLYM: -0.1%
1Y Horizon CLYM +478.59 pp
CVM: -71.22% · CLYM: +407.37%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CVM vs CLYM. Trailing 12-month operating profitability (CVM 0.0% vs CLYM 0.0%) and valuation multiples (CVM 23.0x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CVM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28,558
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-252.5% · 23.0x
CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $22.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $608.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs CLYM Key Questions & Quantitative Answers

As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas CLYM carries 45.7/100 (HOLD) at $9.64 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLYM leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CVM generates $28,558 in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.

CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus CLYM (-29.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.45β · 139% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.